Regenxbio
RGNX
171 hedge funds and large institutions have $717M invested in Regenxbio in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 20 closing their positions.
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more capital invested
Capital invested by funds: $610M → $717M (+$107M)
8% more funds holding
Funds holding: 159 → 171 (+12)
6.54% more ownership
Funds ownership: 84.26% → 90.8% (+6.5%)
14% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $2.02M
23% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$57.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$20.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.03M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$5.72M |
| 5 |
JP Morgan Chase
New York
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.4M |
| 2 |
First Manhattan
New York
|
-$10.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.97M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$8.17M |
| 5 |
Goldman Sachs
New York
|
-$4.59M |
RGNX Hedge Fund Activity: Q4 2023 in Review
171 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2023, worth a combined $717M — up 18% from $610M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RGNX positions and 20 closed out — a net gain of 12 holders — while 47 added to existing stakes and 61 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $57.4M. The largest seller was Balyasny Asset Management, cutting an estimated $10.4M.
- 171 institutional investors held Regenxbio (RGNX) as of Q4 2023, up from 159 in Q3 2023.
- Funds reported $717M of Regenxbio stock for Q4 2023, up 18% quarter-over-quarter.
- 32 funds opened new Regenxbio positions in Q4 2023 and 20 closed out, a net change of +12 holders.
- The largest Regenxbio buyer in Q4 2023 was Morgan Stanley, an estimated $57.4M added.
- The largest Regenxbio seller in Q4 2023 was Balyasny Asset Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2023.